NEW YORK, July 1, 2015 /PRNewswire/ -- The Ulcerative Colitis (UC) treatment market is already undergoing radical change as new, safer products that slow disease progression have come to market or will be launched in the next few years. While 5-ASA and corticosteroids will remain the backbone of treatment, new products that delay progression to steroid treatment or surgery are vying for market space.
Ulcerative Colitis: Dawn of the integrin inhibitors is a comprehensive report from FirstWord packed with the candid opinions of 12 leading North American and European KOLs that present business-critical insights for pharma. Get insights on what they think about current treatment options and the competing clinical and cost benefits that influence their decisions.
When and why will clinicians use these new therapies? Will Entyvio dominate as experience grows? Will the advantages of Genentech's etrolizumab gate crash the market? Will naturally derived low toxicity LT-02 find favour with patients? When is combination therapy best, and in what circumstances? Ulcerative Colitis: Dawn of the integrin inhibitors answers these questions and more.
FirstWord Therapy Trends reports deliver a deep level of unbiased insight from the world's foremost KOLs about the current and future treatment landscapes in key markets. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with KOLs after major events, FirstWord delivers three quarterly Update Bulletins with each report ensuring insights remain current and relevant
Key Benefits
- Know the detailed opinions of leading front-line clinicians on advanced treatments for UC and what they see as critical advantages/disadvantages affecting their decision to prescribe
- Address where new clinical trials could widen use
- Appreciate the important factors affecting the UC area and identify key areas for strategic and tactical action
- Understand how healthcare funding is impacting North American and European KOLs in their day-to-day treatment choices
- Review KOL attitudes to important clinical trials such as COLLECT and SUCCESS
Key Takeaways
- Know the concerns of KOLs and formulate effective strategies for clinician communication and clinical research
- Understand the pivotal role drug pricing plays in clinical thinking and decision making
- Map current treatment options to UC patient groups
- Evaluate the changing competitive landscape and identify solutions that aid KOLs in their practice
- Provides essential decision support information for industry marketers, drug developers, clinical researchers and business planners
Report Features
- Knowledgeable "real world" opinions of leading North American and European KOLs not available elsewhere
- Provides a complete analysis of new and upcoming ulcerative colitis (UC) drugs which will radically alter the treatment algorithm
- Detailed views on the future positioning and competitiveness of all therapies
- Essential insights which answer key business questions in the UC market
KOL Panel
North America
- Prof Edward V Loftus, Jr, MD, Professor of Medicine, Mayo Clinic College of Medicine; Director, Inflammatory Bowel Disease Interest Group, Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota
- Prof Asher Arthur Kornbluth, MD, Clinical Professor of Medicine, Inflammatory Bowel Disease Center, Henry D. Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY
- Prof Hans Herfarth, MD, PhD, Professor of Medicine, University of North Carolina
- Prof Brian G Feagan, Professor of Medicine, Schulich School of Medicine & Dentistry; Gastroenterologist, London Health Sciences Centre; Director, Robarts Clinical Trials, Robarts Research Institute.
- Prof Francis A Farraye, MD, MSc, Professor of Medicine and Clinical Director, Section of Gastroenterology, Boston University School of Medicine, Boston, MA
- Dr Adam S Cheifetz, MD, AGAF, FACG, Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA
Europe
- Prof Gerhard Rogler, Professor of Gastroenterology & Hepatology, Consultant Gastroenterologist, Division of Gastroenterology & Hepatology, Department of Medicine, Zürich University Hospital, Switzerland.
- Prof Laurent Peyrin-Biroulet, MD, PhD, Department of HepatoGastroenterology, University Hospital of Nancy; Professor of Medicine, Head of the IBD unit (Inserm U954), Nancy University Hospital, France
- Dr Silvio Danese, Head, IBD center, Humanitas Clinical and Research Hospital, Italy
- Prof Franck Carbonnel, Professor of Gastroenterology, University of Paris Sud; Head Gastroenterology Department, University Hospital of Bicêtre, France
- Plus two anonymous German KOLs
Answers to Critical Questions
- What is the current clinical view of Entyvio and what is limiting its wider adoption?
- What KOL insights hold lessons for Genentech as it plans for the launch of etrolizumab?
- What opportunities may there be for Simponi and Humira in the expanding paediatric UC sector?
- What clinical trials could help widen the use of Uceris/Cortiment as both an induction and maintenance therapy?
- Lipid Therapeutics' LT-02 is a safe, naturally derived treatment which may be favoured by patients. But what trial, regulatory and production hurdles must it overcome?
- Pfizer's tofacitinib is recognised as an effective UC treatment so why do KOLs see it as a last line therapy?
- What treatment niches do KOLs think InDex Pharmaceuticals and Atlantic Healthcare could respectively carve out for Kappaproct and alicaforsen?
- Combination therapy is being investigated in all stages of UC – what drug combinations do KOLs view positively, and why, and are there implications for manufacturers?
Update Bulletins Offer Ongoing Benefits
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
- Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, December 2014.
- You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date
Read the full report: http://www.reportlinker.com/p02522356-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article